• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, August 8, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

‘Huge breakthrough’ in understanding how the immune system recognises cancer

Bioengineer by Bioengineer
November 24, 2014
in Immunology
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

US researchers have revealed the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them. The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.

Huge breakthrough in understanding how the immune system recognises cancer

This discovery is big, big news for immunotherapy researchers – Dr Sergio Quezada, Cancer Research UK. “This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.

“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.

The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.

Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.

“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.

Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.

In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.

Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.

The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.

More immediately, the findings could be used to predict which patients should be offered ipilimumab, which costs nearly £77,000 for a course of treatment.

“For the first time, it might be feasible to develop a reliable diagnostic test to help guide treatment decisions by predicting who will respond,” said Dr Timothy Chan, who lead the research team.

Story Source:

The above story is based on materials provided by University of Cambridge.

Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

UMass Amherst grad student awarded fellowship for food allergy research

July 23, 2021
IMAGE

Less-sensitive COVID-19 tests may still achieve optimal results if enough people tested

July 22, 2021

Public trust in CDC, FDA, and Fauci holds steady, survey shows

July 20, 2021

USC study shows male-female differences in immune cell function

July 19, 2021
Please login to join discussion

POPULAR NEWS

  • Picture of the horse specimen.

    Ancient DNA clarifies the early history of American colonial horses

    56 shares
    Share 22 Tweet 14
  • The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers

    66 shares
    Share 26 Tweet 17
  • Ill-fated ‘Into the Wild’ adventurer was victim of unfortunate timing, Oregon State study suggests

    39 shares
    Share 16 Tweet 10
  • Skin: An additional tool for the versatile elephant trunk

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Weather/StormsZoology/Veterinary ScienceViolence/CriminalsWeaponryVaccinesUrogenital SystemUniversity of WashingtonVirusVaccineUrbanizationVirologyVehicles

Recent Posts

  • AI pilot can navigate crowded airspace
  • Artificial intelligence tools predict DNA’s regulatory role and 3D structure
  • In simulation of how water freezes, artificial intelligence breaks the ice
  • Ridge-to-reef ecosystem census reveals hidden reservoir for microbiomes
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In